DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.
DRG and its group companies would like to inform you that we have updated our website privacy policy.
If you have a question for our guest, host or DRG please submit it here.
An unprecedented time of scientific innovation
Guest: Houman Ashrafian, Managing Partner, SV Health Investors
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Houman Ashrafian, Managing Partner at SV Health Investors. Houman gives an interesting perspective into how and why biotech investment has remained robust throughout the Covid-19 pandemic. He talks to Mike about his proven track record for establishing companies and the factors he looks for when identifying interesting, investable science. Houman also talks about his work on the Dementia Discovery Fund investment committee, the opportunities they look for as well as the lessons the industry can learn from the immune-oncology revolution and how these can be applied to combat other diseases including neurodegenerative conditions, such as dementia. Houman is optimistic about where the UK is in terms of developing sciences, and what we’ll be able to achieve in this unprecedented time of science innovation. Watch the full interview here.
About our Guest
Houman Ashrafian, Managing Partner, SV Health Investors
Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded five SV companies; Sitryx, Ervaxx, Zarodex, TrexBio and Alchemab. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics. Prior to SV, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma before becoming an SV Venture Partner.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.